BRAF and metastatic melanoma: These preliminary data support TIL therapy with lifileucel as an efficacious and well tolerated therapeutic option for patient with metastatic melanoma who have failed multiple lines of prior therapies including checkpoint inhibitors and BRAF/MEK inhibitors (if BRAF mutated).